News & Events zu NOMAD Power Solutions, Inc (LIXT)LIXTNOMAD Power Solutions, Inc

LIXTE Biotechnology to Acquire 100% of NOMAD Transportable Power Systems

LIXTE Biotechnology provided an update on its previously announced definitive agreement to acquire 100% of NOMAD Transportable Power Systems, the market leader in deployable, utility-grade battery energy storage systems. The Company expects the acquisition to close on or about July 1, 2026, subject to the satisfaction of customary closing conditions and required approvals.

Lixte Biotechnology Acquires 100% of Nomad Transportable Power Systems

Lixte Biotechnology announced that it has entered into a definitive agreement to acquire 100% of Nomad Transportable Power Systems. Upon closing, the company will be renamed Nomad Power Solutions. The company will provide details regarding any ticker symbol change in a subsequent announcement. Under the terms of the definitive agreement, Lixte will acquire 100% of the outstanding equity of Nomad.

Lixte Biotechnology Presents Preliminary Results of LB100 Clinical Trial

Lixte Biotechnology announced the presentation of preliminary results for a clinical trial testing the combination of Lixte's proprietary compound LB100 in combination with Dostarlimab at the 2026 Conference of the Society of Gynecological Cancer, April 10-13, in San Juan, Puerto Rico. At a median follow-up length of 12 months, median OS has not been reached. However, OS probability was 0.84 at 6 months and 0.69 at 12 months. The Disease Control Rate was 40%. Specifically, prior investigation reported markedly prolonged overall survival with ICB in patients with PPP2R1A-mutant OCCC. This suggested that reducing PP2A pharmacologically with LB-100 may enhance the anti-tumor effect of the PD-1 blocking monoclonal antibody, dostarlimab-gxly, in patients with Ovarian Clear Cell Carcinoma lacking the genetic reduction in PP2A.